10-Q: Guided Therapeutics Faces Liquidity Crisis Amid Regulatory Delays

Guided Therapeutics reported increased net losses and negative working capital, with key regulatory approvals for its LuViva device facing delays in China and potential impacts from a U.S. government shutdown.

Summary

• Net loss attributable to common stockholders increased to $2.104 million for the nine months ended September 30, 2025, up from $1.891 million in the prior year.
• Cash and cash equivalents decreased to $87,000 as of September 30, 2025, from $388,000 at December 31, 2024.
• Negative working capital worsened to approximately $5.7 million at September 30, 2025, from $5.0 million at December 31, 2024.
• Accumulated deficit grew to $155.8 million as of September 30, 2025.
• Sales of LuViva devices and disposables significantly increased to $177,462 for the nine months ended September 30, 2025, compared to $5,720 in the same period of 2024.
• Gross profit rose to $113,000 for the nine months ended September 30, 2025, from $4,000 in the prior year.
• The company continues to operate under substantial doubt about its ability to continue as a going concern.
• Key regulatory approvals for the LuViva device in China (NMPA) are delayed until the first half of 2026 due to a mandatory manufacturing site inspection.
• The company's Chinese partner, SMI, is in contractual default, leading to a loss of exclusive rights for LuViva in China.
• A U.S. federal government shutdown could delay FDA approval timelines for the LuViva Advanced Cervical Scan.

Sentiment

Score: 3

Explanation: While there are positive developments in sales growth and clinical trial progress, the company's severe liquidity issues, increasing net losses, negative working capital, and significant accumulated deficit, coupled with regulatory delays and internal control weaknesses, indicate a highly precarious financial position. The going concern warning is a major red flag.

Positives

• Sales of LuViva devices and disposables saw a significant increase to $177,462 for the nine months ended September 30, 2025, up from $5,720 in the prior year.
• Gross profit improved substantially to $113,000 for the nine months ended September 30, 2025, compared to $4,000 in the same period of 2024.
• The U.S. FDA clinical trial for the LuViva Advanced Cervical Scan has surpassed the minimum required enrolled subjects (approximately 460 patients), with data analysis initiated and no adverse events reported.
• Regulatory approval for LuViva was granted in Russia on August 11, 2025, allowing the distribution partner to focus on this larger market.
• A clinical study for LuViva in Turkey, potentially involving up to 20 million annual tests, has been approved by the Turkish Ministry of Health, with funding expected in 2025 and study completion in the first half of 2026.
• The company secured a contract with Hangzhou Dongye Medical Technology Company, Ltd. (HDMT) in China for 35 LuViva devices totaling $700,000, with $100,000 received and three devices delivered.
• Other income increased significantly to $163,087 for the nine months ended September 30, 2025, primarily due to a $183,525 reimbursement from SMI for prior-period costs and $52,400 from the Employee Retention Credit program.

Negatives

• Net loss attributable to common stockholders increased to $2.104 million for the nine months ended September 30, 2025, from $1.891 million in the prior year.
• Cash and cash equivalents declined to $87,000 as of September 30, 2025, from $388,000 at December 31, 2024.
• Negative working capital worsened to approximately $5.7 million at September 30, 2025, from $5.0 million at December 31, 2024.
• The accumulated deficit continued to grow, reaching $155.8 million as of September 30, 2025.
• The company operates under substantial doubt about its ability to continue as a going concern, requiring continuous capital raises.
• The Chinese partner, SMI, is in contractual default due to late payments ($200,000) and failure to provide data, resulting in SMI losing exclusive rights to LuViva in China.
• NMPA approval for LuViva in China is delayed until the first half of 2026 due to a mandatory manufacturing site inspection.
• A prolonged U.S. federal government shutdown could delay FDA regulatory reviews and approvals for LuViva.
• Interest expense increased by 75.2% to $432,752 for the nine months ended September 30, 2025, due to a higher level of outstanding debt.
• A loss on extinguishment of debt of $138,148 was recognized for debt-to-equity exchanges during the nine months ended September 30, 2025.
• Internal control over financial reporting was deemed ineffective as of September 30, 2025, due to a lack of resources for complex transactions and insufficient Board/Audit Committee oversight.
• Several related party notes are outstanding, including an overdue note to Dr. Gene Cartwright ($312,816).

Risks

• Ability to access sufficient debt or equity capital to meet operating and financial needs.
• Extent of dilution of existing stockholders upon issuance, conversion, or exercise of securities from capital raising efforts.
• Risk that certain debt holders may call notes to be paid.
• Effectiveness and ultimate market acceptance of products and ability to generate sufficient sales revenues.
• Whether products in development will prove safe, feasible, and effective.
• Whether and when required regulatory approvals (e.g., FDA, NMPA) will be obtained.
• Need to achieve manufacturing scale-up in a timely manner and ensure efficient manufacturing of sufficient product quantities.
• Lack of immediate alternate sources of supply for some critical components.
• Ability to establish and protect proprietary information, including patent and intellectual property position.
• Impact of the conflict in Ukraine on economic conditions, supply chains, distribution, or regulatory interactions.
• Results related to the termination of the license agreement with SMI and the success of potential new partnership agreements.
• Dependence on potential strategic partners or outside investors for funding, development assistance, clinical trials, distribution, and marketing.
• Prolonged U.S. federal government shutdown could delay FDA regulatory reviews and approvals, affecting commercialization timelines and revenue.
• SMI's delays in NMPA approval and successful marketing in China pose an increasing risk.

Future Outlook

The company expects operating losses to continue for the foreseeable future as it expends substantial resources to complete product commercialization, obtain regulatory clearances, build capabilities, and conduct R&D. It estimates approximately $2.3 million will be needed to fund the business over the next 12 months, primarily for completing the U.S. FDA study and manufacturing production if significant orders are paid in advance. The U.S. FDA study and data analysis are expected to be completed in 2025. NMPA approval in China is anticipated in the first half of 2026, following a mandatory inspection. Funds for a clinical study in Turkey are expected in 2025, with the study concluding in the first half of 2026. Shipment of devices to Indonesia is expected in Q4 2025. The company is evaluating the impact of new accounting standards (ASU 2023-09, ASU 2024-03, ASU 2024-04) on its financial statements.

Management Comments

• We expect operating losses to continue for the foreseeable future as we continue to expend substantial resources to complete commercialization of our products, obtain regulatory clearances or approvals, build our marketing, sales, manufacturing and finance capabilities, and conduct further research and development.
• We estimate that approximately $2.3 million will be needed to fund the business over the next 12 months.
• However, other than completing and filing the US FDA study results, additional expenditures for manufacturing production will be needed only if significant product is ordered and paid for in advance by customers, which is our current policy.
• As of November 1, 2025, approximately 460 patients have been enrolled and tested, which is above the target minimum number needed to file the application with the FDA. Analysis of these data indicate that enough women both with and without cervical disease have been enrolled and tested.
• There have not been any adverse events reported related to the use of LuViva.
• SMI has informed us that a mandatory inspection of their manufacturing site has delayed until of 2026, which is consistent with NMPA approval in the first half of 2026, although there can be no assurance that NMPA approval will occur within the projected time frame, or ever.
• Guided Therapeutics is currently in discussions with a new partner that works with SMI to assume the responsibilities formerly under the purview of SMI.
• The MOH has informed us that this would potentially involve up to 20 million tests annually in Turkey paid for by the Turkish national healthcare system.

Industry Context

Guided Therapeutics operates in the highly competitive and high-failure-rate medical device industry, specifically focusing on biophotonics technology for non-invasive cancer detection. The LuViva device aims to address the need for less invasive cervical cancer screening, particularly in developing countries with limited infrastructure and as a triage tool in developed markets to reduce false positives. The company's challenges with regulatory approvals (FDA, NMPA) and securing consistent sales reflect the significant hurdles faced by new entrants in this capital-intensive sector. The shift in focus to larger markets like Russia and the pursuit of government-funded clinical studies in countries like Turkey indicate a strategy to gain broader market acceptance and scale, which is crucial for medical device companies to overcome initial operating losses and achieve profitability.

Corporate Governance

Legal Proceedings

• No accrual recorded for any potential losses related to pending litigation as of September 30, 2025 and December 31, 2024, as management believes dispositions are not expected to have a material adverse effect.

Related Party Transactions

• Dr. John Imhoff and Michael James (board members) participated in the August 2025 private placement offering.
• Alan Grujic (board member) exchanged a $25,000 note payable and $2,379 of accrued interest for 152,108 units (common stock and warrants) in the August 2025 private placement.
• Dr. Mark Faupel (CEO & President) exchanged a $25,000 note payable for 138,889 units (common stock and warrants) in the August 2025 private placement.
• Dr. John Imhoff and Mr. James also participated in the March 2025 private placement offering.
• Dr. John Imhoff exchanged a $25,000 note payable and $1,307 of accrued interest for 263,069 units (common stock and warrants) in the March 2025 private placement.
• Mr. James exchanged a $25,000 note payable and $1,295 of accrued interest for 262,945 units (common stock and warrants) in the March 2025 private placement.
• Dr. Mark Faupel and Dr. John Imhoff (board members) participated in the exchange of Series C-1 and C-2 Preferred Stock into common stock on March 3, 2025.
• Dr. John Imhoff converted 300 Series D Convertible Preferred shares into 900,000 common shares.
• Dr. Mark Faupel converted 38 Series D Convertible Preferred shares into 114,000 common shares.
• Dr. John Imhoff converted 583 shares of Series E Convertible Preferred Stock into 1,200,000 common shares.
• Mr. Richard Blumberg (board member) converted Series E Convertible Preferred Stock into 932,000 common shares.
• Mr. Alan Grujic (board member) converted Series E Convertible Preferred Stock into 200,000 common shares.
• Revised compensation agreement for CEO Dr. Mark Faupel approved June 3, 2025, including warrants to purchase 4,000,000 shares upon regulatory approvals and 2,000,000 shares upon FDA pivotal trial data filing, and an increased annual compensation of $240,000.
• Dr. John Imhoff received a $160,000 contingently convertible promissory note on September 25, 2025, bearing 10% interest and maturing February 28, 2027.
• Dr. Mark Faupel holds a promissory note with an outstanding balance of $170,471, maturing February 18, 2026.
• Dr. Gene Cartwright holds an overdue promissory note with an outstanding balance of $312,816.
• Richard Fowler, a former executive, holds a note with a remaining principal balance of $13,011, and has forgiven $46,136 of deferred compensation.
• The company issued 596,554 warrants in connection with the August Purchase Agreement and related exchange agreements, with 318,775 issued to board members.
• The company issued 2,571,023 warrants in connection with the March Purchase Agreement and related exchange agreements, with 1,676,014 issued to board members.
• The company issued 75,000 warrants in conjunction with $75,000 of notes payable to board members during the nine months ended September 30, 2024.

Stakeholder Impact

• Shareholders face significant dilution risk from ongoing and future capital raises through common stock and convertible securities, as well as from the conversion of preferred stock and warrants.
• Existing common stockholders are experiencing increased net losses and a growing accumulated deficit, negatively impacting equity value.
• Creditors, particularly those holding overdue notes or notes in default (e.g., 10% Senior Unsecured Convertible Debenture, Dr. Cartwright's note), face uncertainty regarding timely repayment and may exercise conversion rights at potentially dilutive terms.
• Employees may face uncertainty due to the company's going concern issues and plans to curtail operations by reducing discretionary spending and staffing levels if capital cannot be raised.
• Customers and distributors, especially in China, are impacted by regulatory delays and the termination of the SMI license agreement, potentially affecting product availability and market stability.
• The company's ability to secure FDA and NMPA approvals is critical for future revenue generation and market expansion, directly impacting long-term viability for all stakeholders.

Next Steps

• Complete the U.S. FDA clinical study and data analysis in 2025.
• Schedule study site close-out and monitoring visits for the remaining two U.S. clinical sites in November 2025.
• Await NMPA approval for LuViva in China, expected in the first half of 2026 following a mandatory manufacturing site inspection.
• Continue discussions with Hangzhou Dongye Medical Technology Company, Ltd. (HDMT) or other new partners to assume commercialization efforts in China following SMI's default.
• Fulfill the order for 35 LuViva devices to HDMT in China.
• Shift distribution partner Newmars Medical Technologies' emphasis to the Russian market following regulatory approval.
• Receive funds for and conclude the clinical study in Turkey in the first half of 2026.
• Ship four LuViva devices to Indonesia in the fourth quarter of 2025.
• Complete the issuance of securities related to the ongoing private placement offering in the fourth quarter of 2025.
• Continue efforts to raise additional capital to fund operations and regulatory processes.

Key Dates

Recommendation

Guided Therapeutics faces severe financial distress, evidenced by a going concern warning, increasing net losses, negative working capital, and a substantial accumulated deficit. While there are positive developments in sales growth and clinical trial progress, these are overshadowed by significant liquidity challenges, ongoing capital raises that will lead to further dilution, and critical regulatory delays in key markets like China. The ineffective internal controls over financial reporting add another layer of risk. The company's ability to secure sufficient funding on acceptable terms is highly uncertain, and failure to do so could lead to an inability to continue operations or bankruptcy. Given the high risk, precarious financial position, and significant uncertainties, a strong sell recommendation is warranted for investors.

Keywords

Guided Therapeutics, LuViva, Cervical Cancer Detection, Biophotonics, Medical Device, SEC Filing, 10-Q, FDA Approval, NMPA Approval, Clinical Trials, Capital Raise, Going Concern, Risk Factors, Corporate Governance, Financial Performance, Healthcare Technology, Diagnostics